LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

17.83 2.18

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.96

Max

17.84

Põhinäitajad

By Trading Economics

Sissetulek

-56M

-92M

Müük

-46M

167M

Aktsiakasum

-0.74

Kasumimarginaal

-55.292

Töötajad

705

EBITDA

-56M

-80M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+103.57% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-336M

2.2B

Eelmine avamishind

15.65

Eelmine sulgemishind

17.83

Uudiste sentiment

By Acuity

46%

54%

167 / 382 Pingereas Healthcare

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. mai 2025, 23:48 UTC

Kuumad aktsiad

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22. mai 2025, 23:07 UTC

Peamised uudised

Fortescue Energy CEO to Resign in Executive Overhaul

22. mai 2025, 23:03 UTC

Suurimad hinnamuutused turgudel

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22. mai 2025, 23:59 UTC

Market Talk

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22. mai 2025, 23:45 UTC

Market Talk

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22. mai 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

22. mai 2025, 23:23 UTC

Market Talk

Global Energy Roundup: Market Talk

22. mai 2025, 23:23 UTC

Market Talk

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22. mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

22. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. mai 2025, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22. mai 2025, 20:39 UTC

Tulu

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22. mai 2025, 20:36 UTC

Peamised uudised

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22. mai 2025, 20:36 UTC

Peamised uudised
Tulu

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22. mai 2025, 20:32 UTC

Peamised uudised
Tulu

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. mai 2025, 20:27 UTC

Peamised uudised

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22. mai 2025, 20:20 UTC

Peamised uudised

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. mai 2025, 20:17 UTC

Peamised uudised

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22. mai 2025, 20:16 UTC

Tulu

Intchains Group 1Q Rev $18.2M >ICG

22. mai 2025, 20:15 UTC

Peamised uudised

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22. mai 2025, 20:08 UTC

Peamised uudised
Tulu

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22. mai 2025, 20:05 UTC

Peamised uudised

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22. mai 2025, 20:04 UTC

Tulu

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22. mai 2025, 20:04 UTC

Tulu

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22. mai 2025, 20:01 UTC

Tulu

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q Net $68M >WDAY

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q EPS 25c >WDAY

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q Adj EPS $2.23 >WDAY

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q Subscription Revenue $2.06B >WDAY

22. mai 2025, 20:01 UTC

Tulu

Workday 1Q Rev $2.24B >WDAY

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

103.57% tõus

12 kuu keskmine prognoos

Keskmine 37.68 USD  103.57%

Kõrge 60 USD

Madal 18 USD

Põhineb 22 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

22 ratings

14

Osta

8

Hoia

0

Müü

Sentiment

By Acuity

167 / 382 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.